To the Editor:
We read the study by Ding et al 1 with great interest. We congratulate the authors on conducting this large, multicentric study. They have demonstrated that raised levels of aspartate aminotransaminase and direct bilirubin at admission can be used as independent predictors of mortality in patients with coronavirus disease 2019 (COVID-19). They developed a prognostic model with a nomogram that can be used to predict the overall survival probability in patients with COVID-19. Importantly, they have reported that chronic HBV infection is not associated with an increased risk of lethal outcomes in patients with COVID-19. Previous studies have revealed that liver abnormalities occur more frequently in patients with severe COVID-19 and this has been consequential in establishing the association between various liver function abnormalities and their effect on mortality in COVID-19.2 This is due to the multiplier effect of multiple organ dysfunction, cytokine storm, drug effects and hypoxic liver injury, rather than the direct cytopathic effect of the SARS-CoV-2. Kulkarni et al. 3 performed a meta-analysis of 20,874 patients and reported that 3.6% of patients had chronic liver disease (CLD). The odds of developing severe COVID-19 in patients with CLD was 0.81 (95% CI 0.31–2.09; p = 0.67) compared to non-CLD patients. COVID-19 patients with elevated liver chemistries had higher risk of mortality (odds ratio [OR] 3.46 [2.42–4.95, p <0.001]) and severe disease (OR 2.87 [95% CI 2.29–3.6, p <0.001]) compared to patients without elevated liver chemistries. In this study,1 around 61.8% patients had some abnormal liver chemistry during the course of hospitalization. However, there are some important issues that have not been addressed in the paper.
The study fails to identify underlying CLD as a predictor of worse outcome, possibly due to the small number of patients in the study. Also, the severity of liver disease in terms of various scoring systems has not been corelated with the outcomes. Only 11 individuals had compensated cirrhosis and 3 had decompensated cirrhosis. Standard severity scoring systems like Child-Pugh and model for end-stage liver disease for cirrhosis and Maddrey’s discriminant function for alcoholic hepatitis have not been described and correlated with survival.4 , 5
Although most patients developed some transaminitis during admission, there were several confounding factors that blur the direct association of liver dysfunction attributable to COVID-19. Cai et al. 6 reported use of drugs, systemic inflammation, secondary sepsis, polypharmacy, shock and hypoxia as contributors to liver injury in COVID-19. The presence of hypoxic injury7 is also a contributor to liver injury and has not been described in this study. It is evident from the description that the hospitalized patients in this cohort were sick, with most requiring high flow oxygen or invasive ventilation which could have contributed independently to liver injury. Also, the use of various medications during the hospital course should be included in the analysis. The use of hepatotoxic drugs like lopinavir and ritonavir have been shown to be associated with liver injury.6 Alcohol abuse or use of Chinese herbal medication before admission should also be determined and adjusted for in multivariate analysis as that can be a potential contributor to liver injury.8 The large number of drugs used in clinical trials and variable management of such patients based on evolving evidence also makes comparisons of cohorts difficult.9
In conclusion, we believe that Ding et al. 1 have meticulously analyzed various liver biochemistry abnormalities during COVID-19. However, the retrospective nature of the cohort, limitations of data, lack of external validation and other confounding factors described merit further investigation and research. It would be premature to attribute deranged liver function to COVID-19 infection alone with the available evidence.
Financial support
The authors received no financial support to produce this manuscript.
Authors' contributions
AS: writing and critical revision, MP: writing and critical revision, VS: writing and critical revision.
Conflict of interest
The authors declare no conflicts of interest.
Please refer to the accompanying ICMJE disclosure forms for further details.
Footnotes
Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhep.2021.03.010
Supplementary data
The following is the supplementary data to this article:
References
- 1.Ding Zy, Li Gx, Chen L., Shu C., Song J., Wang W., et al. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol. 2021;74(6):1295–1302. doi: 10.1016/j.jhep.2020.12.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Guan W-j, Ni Z-y, Hu Y., Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kulkarni A.V., Kumar P., Tevethia H.V., Premkumar M., Arab J.P., Candia R., et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther. 2020 Aug;52(4):584–599. doi: 10.1111/apt.15916. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Lavarone M., D'Ambrosio R., Soria A., Triolo M., Pugliese N., Del Poggio P., et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020;73(5):1063–1071. doi: 10.1016/j.jhep.2020.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Moon A.M., Webb G.J., Aloman C., Armstrong M.J., Cargill T., Dhanasekaran R., et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. J Hepatol. 2020;73(3):705–708. doi: 10.1016/j.jhep.2020.05.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Cai Q., Huang D., Yu H., Zhu Z., Xia Z., Su Y., et al. COVID-19: abnormal liver function tests. J Hepatol. 2020;73(3):566–574. doi: 10.1016/j.jhep.2020.04.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ebert E.C. Hypoxic liver injury. Mayo Clinic Proc. 2006;81(9):1232–1236. doi: 10.4065/81.9.1232. [DOI] [PubMed] [Google Scholar]
- 8.Jing J., Teschke R. Traditional Chinese medicine and herb-induced liver injury: comparison with drug-induced liver injury. J Clin Transl Hepatol. 2018;6(1):57–68. doi: 10.14218/JCTH.2017.00033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Wong G.L., Wong V.W., Thompson A., Jia J., Hou J., Lesmana C.R.A., et al. Asia-pacific working group for liver derangement during the COVID-19 pandemic. Management of patients with liver derangement during the COVID-19 pandemic: an asia-pacific position statement. Lancet Gastroenterol Hepatol. 2020;5(8):776–787. doi: 10.1016/S2468-1253(20)30190-4. Epub 2020 Jun 23. PMID: 32585136; PMCID: PMC7308747. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.